|
|
 |
|
|
|
|
Sleep apnea, sleep-disordered breathing, and intermittent
hypoxia have been identified and linked in latest research to
almost all major fatal medical conditions, from heart attack,
stroke, diabetes, COPD cancer, and major depressive disorders.
Current main-stream treatment options are unsatisfactory, and
the entire world is looking for a better or best solution.
This market is one of the most explosive and largely untapped
markets.
SleepApneaUSA.net, founded by Dr. Jin Zhou, relied upon
the latest research and clinically developed ZHT - Zhou's
Hypoxicology Therapy to discover a possible cure for sleep apnea
and provide an alternative care to those who can't tolerate
CPAP,"sleeping mask". |
|
|
|
|
|
|
We are looking for
visionary investors, strategic partners, business alliance and
concerned healthcare providers to advance our goals, to find and
provide with possible cure for sleep apnea, and its related
major fatal medical conditions.
This web site is
mainly for visionary investors, strategic business partners and
concerned healthcare providers. |
|
|
|
|
         
|
ZHT
Unlimited Potentials & Applications:
Unlike other therapies currently used for sleep apnea,
ZHT (Zhou's hypoxicology Therapy) identifies the root
causes of sleep apnea, employs human natural power,
human systemic defense reflexes, volitional
resuscitations to eliminate and relieve not only sleep
apnea but also many other intermittent hypoxia related
health problems.
Association Between Sleep Apnea and
Death Points to Need to
Examine Treatments, Modify Devices (AScribe
- USA) What is ZHT?
Zhou’s Hypoxicology
Therapy (ZHT) was pioneered/developed by Dr. Jin
Zhou, DC, in late 2004. It is a new medical clinical concept of etiology, pathophysiology and clinical therapy, which identifies Trachea Caudal
Displacement (TCD) & Vocal Cord dysfunction (VCD) induced chronic
intermittent hypoxia through Silent Upper Airway Resistance Syndrome (SUARS)
and Frequent & Recurrent Upper Airway Collapse Syndrome (FRUACS) or
sleep-disordered breathing, as well as
nocturnal gastroesophageal reflux (NGER) as a new fundamental physio-pathological
mechanism, as one of the main causes, for mild to moderate but
prolonged hypoxia for most illness & diseases for worldwide mortality
and disability, from pain & arthritis, heart attack, hypertension,
diabetes, anxiety & depression to almost every illness & diseases.
Based currently
published research and ZHT clinical observations, ZHT may have
potential to provide therapeutic values for diabetes, cancers,
Alzheimer's disease, Amyotrophic lateral sclerosis (ALS) and many
more sleep disordered breathing (SDB) and chronic intermittent
hypoxia related major illness and diseases.
ZHT in News and Actions :
06:18 PM Mountain Standard Time on
Tuesday, November 22, 2005 Phoenix News| azfamily - KTVK| News for
Phoenix, Arizona | OnTV: Good Evening Arizona Hotline.
|
|
